Showing 9,421 - 9,440 results of 226,405 for search '(( a ((a decrease) OR (linear decrease)) ) OR ( a ((greater decrease) OR (largest decrease)) ))', query time: 1.33s Refine Results
  1. 9421

    Co-Depletion of Cathepsin B and uPAR Induces G0/G1 Arrest in Glioma via FOXO3a Mediated p27<sup>Kip1</sup> Upregulation by Sreelatha Gopinath (238422)

    Published 2010
    “…These effects could be mediated by αVβ3/PI3K/AKT/FOXO pathway as observed by the decreased αVβ3 expression, PI3K and AKT phosphorylation accompanied by elevated FOXO3a levels. …”
  2. 9422

    Image 4_The N6-methyladenosine RNA epigenetic modification modulates the amplification of coxsackievirus B1 in human pancreatic beta cells.tif by Maressa Fernandes Bonfim (6700379)

    Published 2024
    “…Using small interfering RNA (siRNA) targeting m6A writers and erasers, we observed that downregulation of m6A writers increases CVB1 amplification, while the downregulation of m6A erasers decreases it. …”
  3. 9423
  4. 9424
  5. 9425
  6. 9426
  7. 9427
  8. 9428

    RA increases S100β+ and decreases peripherin+ cell prevalence while EDN3 decreases S100β+ cell prevalence. by Jonathan M. Gisser (456149)

    Published 2013
    “…(A) The proportion of S100β+ cells was enriched by RA and decreased in response to EDN3 (B) RA increased, and EDN3 decreased the fraction of proliferating S100β+ cells. …”
  9. 9429
  10. 9430
  11. 9431
  12. 9432
  13. 9433
  14. 9434

    Immunohistochemical staining for endothelial cells (CD146) and astrocytes (GFAP) in the lumbar spinal cord of G93A mice at early and late stages of disease. by Svitlana Garbuzova-Davis (81764)

    Published 2013
    “…In G93A mice at (D, E) early or (F, G) end-stage of disease, decreased CD146 antigen expression by endothelial cells (green, arrowheads) was observed. …”
  15. 9435
  16. 9436
  17. 9437
  18. 9438
  19. 9439
  20. 9440

    FASN inhibition decreased β-catenin expression. by Pascal Gelebart (174443)

    Published 2012
    “…<p>The MCL cell line Mino was treated with Orlistat (A) or siRNA (B) to inhibit or knock-down FASN, respectively. …”